

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA BIOTECH SERVICES HOLDINGS LIMITED

中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

VOLUNTARY ANNOUNCEMENT CLINICAL TRIAL RESULTS PRESENTED AT 2024 ASCO ANNUAL MEETING

This announcement is made by China Biotech Services Holdings Limited (the “**Company**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, Shanghai Longyao Biotech Company Limited* (上海隆耀生物科技有限公司), an indirect non-wholly owned subsidiary of the Company, announced the results of the phase I clinical study (“**Phase I Study**”) of LY007 Cellular Injection, a novel CD20-targeted autologous chimeric antigen receptor T cell therapy in patients with relapse/refractory B-cell non-Hodgkin lymphoma (“**B-NHL**”), at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in the form of poster presentation.

Large B-cell lymphoma (“**LBCL**”) is a common subtype of B-NHL, and the majority of patients can be cured by standard immunochemotherapy regimens. However, approximately 40% of patients still face relapse/refractory dilemmas after first-line treatment. The Phase I Study was conducted to evaluate the safety and tolerability of LY007 Cellular Injection for the treatment of relapse/refractory B-NHL patients. The Phase I Study demonstrated that LY007 Cellular Injection was well tolerated at the dose levels up to 5.0×10^6 cells/kg and showed a favorable dose-response relationship for the treatment of relapse/refractory B-NHL. LY007 Cellular Injection is expected to provide a new treatment option for LBCL patients.

As of 25 December 2023, 9 patients were treated with single LY007 Cellular Injection infusions at 3 dose levels with a median follow-up of 5.09 (range 0.92-18.10) months. 89% (8/9) of patients had extranodal involvement, 78% (7/9) had an International Prognostic Index (IPI) score of ≥ 2 , 44% (4/9) had a maximum tumor length of ≥ 5 cm and two patients had a maximum tumor length of > 8 cm.

By order of the Board
China Biotech Services Holdings Limited
Liu Xiaolin
Chairman and Executive Director

Hong Kong, 5 June 2024

As at the date of this announcement, the board of Directors comprises three executive Directors, namely, Mr. Liu Xiaolin (Chairman), Mr. He Xun, and Mr. Huang Song; one non-executive Director, namely, Ms. Chui Hoi Yam; and three independent non-executive Directors, namely, Mr. Yan Guoxiang, Dr. Ho Ivan Chun Kit and Mr. Qian Hongji.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.

* *The English transliteration of the Chinese name is for identification purposes only. If there is any inconsistency, the Chinese name shall prevail.*